18.04.2011 • News • Rhodia • People

Louis Neltner Appointed Rhodia Vice President, Research & Development

Rhodia has apponted Louis Neltner as vice president, Research & Development. He will be a member of the group's management committee.

Alumnus of the Ecole Normale Supérieure, Louis Neltner, holds a PhD in Physics and is an engineer from France's Corps des Mines. He started his career in the public sector in 1999, at the French Telecommunications Regulatory Authority (ART), then moved to the general Inspectorate of Finance. Manager at McKinsey since 2004, he directed complex strategy-related projects and transformation programs for large companies in industry and high-tech sectors.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Top-Feature

most read

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.